In the matter of stocks, because of the help of the system, after I have a bottom in my heart, the communication with the investment consultant will be more difficult.

No matter how he persuaded him, Wu Zhou stood still.

Stick to sell plus stick to short.

In the end, the investment advisor could only compromise and continue to do what Wu Zhou said.

The next day, unsurprisingly, the ZF department sent out a number of good news to boost confidence in the stock market.

Many stocks have even turned red as a result, but not Tesla.

At the same time, short-selling ETFs are also being bought, and this is the best time to buy.

In Wu Zhou in Huaxia, Wu Zhou would take a glance at these buying and selling transactions early the next morning.

But after turning his head, he had to get busy again.

Medical device companies are still consolidating.

But Aiying Biopharmaceutical Company has been sorted out.

Talents are also arriving one after another.

In the eyes of the management and employees of Aiying Biotech, watching the entry of big bulls one by one, these old employees who are at ease to do R&D are becoming more and more confident.

And after these big bulls joined the company, they also found that what they promised before arrived in the account as soon as possible.

It's like the 100 million R&D fund, which will arrive when it arrives.

As for the work content of the company, they don't need to care about the social problems of those Rausch, they just need to stay in the laboratory with peace of mind and do the experiments they like.

As for the ordinary researchers below, although many of them may not know each other, after working for a while, they can feel the strength of each other.

Leaders with such strong R&D strength have joined the company, so why worry about future development.

All of this has gradually strengthened their confidence.

He even began to look forward to the future, and in the future, whether Aiying Biotech would become one of the world's leading pharmaceutical companies in the future.

Biomedicine is very difficult to do.

Many netizens' comments on Wu Zhou, although they are emotional and may be a little ugly, are not entirely wrong.

If Wu Zhou is a person who does not have a system, or if Wu Zhou does not have the directional push function of the system.

In the medical field, Wu Zhou probably didn't dare to get involved.

For example, the top pharmaceutical foreign company, Roche Pharmaceutical, has such a description diagram.

10000000000 Swiss francs (about the same value as the US dollar).

7000874 hours of work (equivalent to one person, 799 years of endless work)

6587 times of scientific research

423 researchers

1 drug

This is the drug development process of Roche Pharmaceuticals, a top pharmaceutical company, under normal mode.

Generally, an early drug research is to screen compounds, about 5000-10000 compounds to screen out 1 auspicious number, such as 250 for preclinical research.

This process generally takes 3-6 years.

About 5 of these 250 compounds can enter clinical studies, which is phase 1, phase 2 and phase 3 clinical trials, and the process is about 6-7 years.

Finally, it is expected to approve 1, which is a 20% success rate, and this process takes about 0.5-2 years.

In total, the shortest time is 3 + 6 + 0.5 = 9.5 years.

Judging by these timings.

In the first item, compound screening, less than 5% of the nearly 10,000 compounds can enter the next round.

In other words, 95% of the work time is wasted.

If the system participates in the screening, it is a 20-fold increase in sales, or even a one-step process, directly selecting the last drug that can be marketed.

That's a 10,000-fold increase in efficiency.

Although the R&D cost cannot be saved tens of thousands of times.

But a tenfold and hundredfold savings is not a big problem.

The conclusion is that others have tens of billions, and Wu Zhou is about 1-1 billion, and he can almost make one.

Of course, the above only exists in theory, and it is certainly not possible to do so in practice.

After all, the success rate is unreasonably high, and it is easy to be noticed.

Of course, Wu Zhou also thought of some compromises.

And it's already being implemented.

First of all, from the perspective of compound screening, there are some geniuses who are born with good luck, and Wu Zhou's company who happened to be very lucky recruited him, and he happened to come to the company's R&D department, and then.

Of course, pure luck will not last long, in the early stage, Wu Zhou can try everything to accelerate the development of the company, but in the later stage, the company must be self-circulating.

Only in this way can it last for a long time, and only then can there be a steady stream of good things coming out.

Of course, the most important thing is that only in this way can Wu Zhou's time be free.

Biochemical materials are the sinkhole industry jokingly called by many netizens and students, the main reason is that the employment is relatively poor, and the salary is much lower than that of the popular industry.

However, wages can only represent a moment, not a lifetime, and the importance of these industries is still self-evident.

It's just that the market demand is not so much, and in addition, we have a large population and more people, and the salary has also decreased.

So, after Wu Zhou got in touch with these universities.

The recruitment process is going very well, and the latest early approval is already underway.

Colleges and universities above 211, the starting salary of undergraduate is 10,000+, master's is 1.5-2w+, and doctoral is 3w+.

The salary package given is about double the current industry price.

Of course, this is for ordinary talents, special talents, and this salary is definitely not good.

The company has a special genius program, which is modeled after Huawei's 'genius program'.

Give a full and free R&D environment, R&D funds, plus high salaries in the industry.

Geniuses are different, and of course the salary is different, purely from a salary point of view.

It is mainly divided into three grades.

The third tranche is, 70-1 million

The second tranche is, 1.3 million to 1.5 million

The first tranche is, 1.8 million to 2 million

Breakthroughs in a field often rely on one or two geniuses.

In addition, Wuzhou Company's Aiying Biology, the '100 Talents Project' that is still being carried out, are almost all top-level scientific research talents, and some people have not made real achievements, but the time has not come, or the research is in the wrong direction, and time is wasted.

After all, success depends not only on strength, but also on luck.

Wu Zhou will give them full opportunities and directions, and even find them a suitable partner, so that they can encounter more brilliant results.

With the help of the system, the future is still very promising.

Again, it's an artificial intelligence system.

This is also one of the cutting-edge technologies of the moment.

Artificial intelligence systems have very strong innate advantages, which can greatly help human beings improve R&D productivity and greatly improve R&D efficiency and progress.

And as long as there is sufficient data, AI can continue to grow through self-learning.

It's almost impossible to retrieve that big data with the human brain, but for artificial intelligence, these are the basic exercises.

And this, in fact, Huaxia is still very advantageous, at present, in the world in the artificial field, there are actually only two players, one is us.

There are actually top experts, top companies, and top products in the field of artificial intelligence in China.

Of course, this involves spending money.

Fortunately, Wu Zhou has a lot of money

Of course, all of the above is still opportunistic 'step-by-step'.

No matter how to improve efficiency, some processes require so much time.

Therefore, if a new drug is developed from 0, it is estimated that Wu Zhou's Aiying Biotech will start to have breakthrough results in ten years

It's still too long.

We still have to think of something new.

For example, buy, buy, buy.

(End of chapter)